by admin | Oct 13, 2018 | All News, Industry News
– First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis based on an intra-patient comparison – – Only medicine that can be self-administered subcutaneously once weekly, every two weeks or every four weeks for hemophilia A with...
by admin | Dec 29, 2016 | All News, Industry News
Emicizumab prophylaxis reduced the number of bleeds over time compared to no prophylaxis in people with hemophilia A and inhibitors to factor VIII South San Francisco, CA December 21, 2016 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today...
by admin | Aug 31, 2016 | All News, Industry News
MASAC Document #243 The following recommendation was approved by the Medical and Scientific Advisory Council (MASAC) on June 17, 2016, and adopted by the NHF Board of Directors on June 28, 2016. The development of inhibitors (neutralizing antibodies to factor VIII) is...
by admin | Mar 21, 2016 | All News, Industry News
Whippany, NJ, March 17, 2016 – The U.S. Food and Drug Administration has approved Bayer’s KOVALTRY® Antihemophilic Factor (Recombinant), an unmodified, full-length factor VIII compound for the treatment of hemophilia A in children and adults. The approval is based on...
by admin | Mar 11, 2016 | All News, Industry News
In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days, resulting in a median annualized spontaneous bleeding rate (AsBR) of 0.00 IDELVION, CSL Behring’s long-acting recombinant albumin fusion protein, delivers on the company’s...
by admin | Jan 28, 2016 | All News, Industry News
FDA News Release For Immediate Release January 28, 2016 Release The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in...
